Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49


Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine.

Boudousquié C, Boand V, Lingre E, Dutoit L, Balint K, Danilo M, Harari A, Gannon PO, Kandalaft LE.

Vaccines (Basel). 2020 Jan 14;8(1). pii: E25. doi: 10.3390/vaccines8010025.


Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ.

Germann M, Zangger N, Sauvain MO, Sempoux C, Bowler AD, Wirapati P, Kandalaft LE, Delorenzi M, Tejpar S, Coukos G, Radtke F.

EMBO Mol Med. 2020 Jan 9;12(1):e10681. doi: 10.15252/emmm.201910681. Epub 2019 Dec 2.


A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.

Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE.

J Transl Med. 2019 Nov 26;17(1):391. doi: 10.1186/s12967-019-02133-w.


Believe in yourself, and enjoy the ride.

Kandalaft LE.

EBioMedicine. 2019 Nov;49:22. doi: 10.1016/j.ebiom.2019.10.049. Epub 2019 Nov 6. No abstract available.


Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, Kammula US, Orcurto A, Zimmermann S, Trueb L, Klebanoff CA, Lotze MT, Kandalaft LE, Coukos G.

Ann Oncol. 2019 Dec 1;30(12):1902-1913. doi: 10.1093/annonc/mdz398.


A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.

Bassani-Sternberg M, Digklia A, Huber F, Wagner D, Sempoux C, Stevenson BJ, Thierry AC, Michaux J, Pak H, Racle J, Boudousquie C, Balint K, Coukos G, Gfeller D, Martin Lluesma S, Harari A, Demartines N, Kandalaft LE.

Front Immunol. 2019 Aug 8;10:1832. doi: 10.3389/fimmu.2019.01832. eCollection 2019.


Immunotherapy in Ovarian Cancer: Are We There Yet?

Kandalaft LE, Odunsi K, Coukos G.

J Clin Oncol. 2019 Sep 20;37(27):2460-2471. doi: 10.1200/JCO.19.00508. Epub 2019 Aug 12. No abstract available.


Rational combinations of immunotherapy with radiotherapy in ovarian cancer.

Herrera FG, Irving M, Kandalaft LE, Coukos G.

Lancet Oncol. 2019 Aug;20(8):e417-e433. doi: 10.1016/S1470-2045(19)30401-2. Epub 2019 Jul 29. Review. Erratum in: Lancet Oncol. 2019 Sep;20(9):e468.


18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.

Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V, Peters S, Krueger T, de Leval L, Kandalaft LE, Nicod-Lalonde M, Romero P, Prior JO, Coukos G, Schaefer N.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1859-1868. doi: 10.1007/s00259-019-04348-x. Epub 2019 Jun 18.


Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.

Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, Conejo-Garcia J, Ramay HR, Montone KT, Powell DJ Jr, Gimotty PA, Facciabene A, Jackson DG, Weber JS, Rodig SJ, Hodi SF, Kandalaft LE, Irving M, Zhang L, Foukas P, Rusakiewicz S, Delorenzi M, Coukos G.

Cancer Cell. 2019 Jun 10;35(6):885-900.e10. doi: 10.1016/j.ccell.2019.05.004.


Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.

Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE.

Front Immunol. 2019 Apr 11;10:766. doi: 10.3389/fimmu.2019.00766. eCollection 2019. Review.


The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.

Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, Teijeira A, Kandalaft LE, Romero P, Coukos G, Neyns B, Sancho D, Melero I, de Vries IJM.

J Immunother Cancer. 2019 Apr 18;7(1):109. doi: 10.1186/s40425-019-0580-6. Review.


IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine.

Mookerjee A, Graciotti M, Kandalaft LE.

Cancers (Basel). 2019 Jan 4;11(1). pii: E40. doi: 10.3390/cancers11010040.


Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?

Martin Lluesma S, Graciotti M, Chiang CL, Kandalaft LE.

Vaccines (Basel). 2018 Nov 23;6(4). pii: E79. doi: 10.3390/vaccines6040079. Review.


In vivo cancer vaccination: Which dendritic cells to target and how?

Chiang CL, Kandalaft LE.

Cancer Treat Rev. 2018 Dec;71:88-101. doi: 10.1016/j.ctrv.2018.10.012. Epub 2018 Oct 25. Review.


Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches.

Digklia A, Duran R, Homicsko K, Kandalaft LE, Hocquelet A, Orcurto A, Coukos G, Denys A.

Cardiovasc Intervent Radiol. 2019 Sep;42(9):1221-1229. doi: 10.1007/s00270-018-2074-1. Epub 2018 Sep 12. Review.


Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.


Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.

Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.


Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.

Guo Y, Hu J, Wang Y, Peng X, Min J, Wang J, Matthaiou E, Cheng Y, Sun K, Tong X, Fan Y, Zhang PJ, Kandalaft LE, Irving M, Coukos G, Li C.

Eur J Cancer. 2018 Feb;90:111-121. doi: 10.1016/j.ejca.2017.10.035. Epub 2018 Jan 4.


Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.

Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon PO, Kandalaft LE, Coukos G, Gfeller D.

PLoS Comput Biol. 2017 Aug 23;13(8):e1005725. doi: 10.1371/journal.pcbi.1005725. eCollection 2017 Aug.


Cancer Vaccines in Ovarian Cancer: How Can We Improve?

Martin Lluesma S, Wolfer A, Harari A, Kandalaft LE.

Biomedicines. 2016 May 3;4(2). pii: E10. doi: 10.3390/biomedicines4020010. Review.


Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.

Zsiros E, Dangaj D, June CH, Kandalaft LE, Coukos G.

Oncoimmunology. 2015 Oct 19;5(5):e1062210. doi: 10.1080/2162402X.2015.1062210. eCollection 2016 May.


Opportunities in immunotherapy of ovarian cancer.

Coukos G, Tanyi J, Kandalaft LE.

Ann Oncol. 2016 Apr;27 Suppl 1:i11-i15. doi: 10.1093/annonc/mdw084. Review.


Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers.

Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L.

Cancer Cell. 2015 Oct 12;28(4):529-540. doi: 10.1016/j.ccell.2015.09.006.


Whole Tumor Antigen Vaccines: Where Are We?

Chiang CL, Coukos G, Kandalaft LE.

Vaccines (Basel). 2015 Apr 23;3(2):344-72. doi: 10.3390/vaccines3020344. Review.


Personalized approaches to active immunotherapy in cancer.

Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE.

Biochim Biophys Acta. 2016 Jan;1865(1):72-82. doi: 10.1016/j.bbcan.2015.07.004. Epub 2015 Aug 1. Review.


The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G.

Clin Cancer Res. 2015 Jun 15;21(12):2840-50. doi: 10.1158/1078-0432.CCR-14-2777. Epub 2015 Feb 23.


Potential approaches for more successful dendritic cell-based immunotherapy.

Chiang CL, Balint K, Coukos G, Kandalaft LE.

Expert Opin Biol Ther. 2015 Apr;15(4):569-82. doi: 10.1517/14712598.2015.1000298. Epub 2015 Jan 2. Review.


Immunotherapy for ovarian cancer: recent advances and perspectives.

Zsiros E, Tanyi J, Balint K, Kandalaft LE.

Curr Opin Oncol. 2014 Sep;26(5):492-500. doi: 10.1097/CCO.0000000000000111. Review.


A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G.

Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.


A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Kandalaft LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R, Coukos G.

J Transl Med. 2013 Jun 18;11:149. doi: 10.1186/1479-5876-11-149.


Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G.

Oncoimmunology. 2013 Jan 1;2(1):e22664.


Conference scene: Immune signatures in the tumor and beyond.

Kandalaft LE, Kalos M, Melief CJ, Speiser DE, Coukos G.

Immunotherapy. 2012 Aug;4(8):761-72. doi: 10.2217/imt.12.70.


A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Coukos G.

J Transl Med. 2012 Aug 3;10:157. doi: 10.1186/1479-5876-10-157.


Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.

Chiang CL, Hagemann AR, Leskowitz R, Mick R, Garrabrant T, Czerniecki BJ, Kandalaft LE, Powell DJ Jr, Coukos G.

PLoS One. 2011;6(12):e28732. doi: 10.1371/journal.pone.0028732. Epub 2011 Dec 14.


Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.

Chiang CL, Maier DA, Kandalaft LE, Brennan AL, Lanitis E, Ye Q, Levine BL, Czerniecki BJ, Powell DJ Jr, Coukos G.

J Transl Med. 2011 Nov 14;9:198. doi: 10.1186/1479-5876-9-198.


Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.

Chiang CL, Kandalaft LE, Coukos G.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):150-82. doi: 10.3109/08830185.2011.572210. Review.


Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.

Kandalaft LE, Motz GT, Duraiswamy J, Coukos G.

Cancer Metastasis Rev. 2011 Mar;30(1):141-51. doi: 10.1007/s10555-011-9289-9. Review.


Clinical translation section: accelerating the pace from bench to bedside.

Kandalaft LE, Coukos G.

J Transl Med. 2011 Jul 21;9:116. doi: 10.1186/1479-5876-9-116. No abstract available.


Immunotherapy for ovarian cancer: what's next?

Kandalaft LE, Powell DJ Jr, Singh N, Coukos G.

J Clin Oncol. 2011 Mar 1;29(7):925-33. doi: 10.1200/JCO.2009.27.2369. Epub 2010 Nov 15. Review.


Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin.

Kandalaft LE, Motz GT, Busch J, Coukos G.

Curr Top Microbiol Immunol. 2011;344:129-48. doi: 10.1007/82_2010_95. Review.


The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Kandalaft LE, Singh N, Liao JB, Facciabene A, Berek JS, Powell DJ Jr, Coukos G.

Gynecol Oncol. 2010 Feb;116(2):222-33. doi: 10.1016/j.ygyno.2009.11.001. Epub 2009 Dec 2. Review.


Endothelin B receptor, a new target in cancer immune therapy.

Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G.

Clin Cancer Res. 2009 Jul 15;15(14):4521-8. doi: 10.1158/1078-0432.CCR-08-0543. Epub 2009 Jun 30. Review.


Differentially expressed nucleolar transforming growth factor-beta1 target (DENTT) exhibits an inhibitory role on tumorigenesis.

Kandalaft LE, Zudaire E, Portal-Núñez S, Cuttitta F, Jakowlew SB.

Carcinogenesis. 2008 Jun;29(6):1282-9. doi: 10.1093/carcin/bgn087. Epub 2008 Apr 1.


Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung.

Sakagami M, Omidi Y, Campbell L, Kandalaft LE, Morris CJ, Barar J, Gumbleton M.

Pharm Res. 2006 Feb;23(2):270-9. Epub 2006 Jan 1.


Constitutive expression of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures.

Campbell L, Abulrob AN, Kandalaft LE, Plummer S, Hollins AJ, Gibbs A, Gumbleton M.

J Pharmacol Exp Ther. 2003 Jan;304(1):441-52.


Supplemental Content

Loading ...
Support Center